 Overactive bladder (OAB) is a urologic syndrome characterized by urinary urgency, with or without urge incontinence, usually in combination with frequent urination and nocturia 1, 2 .
 Symptoms: -Urgency: Sudden, compelling desire to pass urine that is difficult to defer.
-Frequency: Urinating more than eight times in a day.
-Urge incontinence: Involuntary loss of urine occurring for no apparent reason while feeling urinary urgency. -Nocturia: Interrupted sleep because of an urge to void twice or more a night.
 The reluctance of those with OAB to seek medical advice can leave a considerable part of the population untreated, with significant personal and societal costs.
BACKGROUND

Data Source
 Data were taken from the 5EU (France, Germany, Italy, Spain, and UK) 2013 National Health and Wellness Survey (NHWS), a cross-sectional survey representative of the total adult populations in each 5EU market. In total, 62,000 respondents participated in the survey in 2013.
Sample
 The 1,347 respondents who reported a diagnosis of OAB (Table 1) were excluded from the analyses.
 Among the remaining 60,653 respondents, 17,519 reported symptoms compatible with OAB (red), while 43,134 did not report any (green).
Variables
 Grouping variable: Presence of OAB symptoms: -At least one of the symptoms included in the definition (urgency, frequency, urge incontinence, nocturia) experienced in the past 6 months.
 Health-related Quality of Life (HRQoL):
The SF-36v2 was used to assess HRQoL. This is a generic health survey and one of the most commonly used patient-reported outcomes measures -Only full-time, part-time, or self-employed respondents provided data for absenteeism, presenteeism, and overall work impairment. All respondents provided data for activity impairment.
 Other variables of interest: Demographics (age, gender, marital status, education, income, and employment status), BMI, alcohol and smoking behavior.
Analysis
 Bivariate analyses between the symptomatic and asymptomatic group were performed with chi 2 tests for categorical variables and t-tests for cardinal variables.
 A multivariate regression model tested the relationship between reporting OAB symptoms, sociodemographics, and the three Quality of Life components measured by the SF-36v2 (MCS, PCS, and Health Utility) 5 .
METHODS
 The OAB group, compared to the controls, had a higher percentage of women, was older, with a lower education level, less were in a relationship, less were employed, more were obese, they had lower HRQoL, lower work productivity, and higher activity impairment; see Table 2 . All differences were significant (p < 0.001).
RESULTS
 Respondents reporting symptoms compatible with OAB but that are not treated and would not be captured by clinical studies are significantly worse-off than the rest of the population, e.g., in their quality of life, income, and work productivity.
 Regression-adjusted decrement of OAB symptoms exceeds the 3-point burden usually considered the minimally-important difference for MCS and PCS scores 3 .
 This suggests a significant unmet need for treatment of OAB symptoms in Europe.
CONCLUSIONS
 Further analyses should complete the description of the burden and costs of non-treated OAB patients (work productivity, healthcare resource utilization, and indirect costs).
LIMITATIONS
 To assess the health-related quality of life (HRQoL) burden of individuals in Europe who experience symptoms of OAB but are not treated.
OBJECTIVE
 The individual linear regressions on work productivity and activity impairment measured by the WPAI (Absenteeism, Presenteeism, Overall Work Impairment, and Activity Impairment) confirm that the presence of OAB symptoms results in a significant increase in all four indexes (p<0.05); see Figure 1b .
 After controlling for all other variables, all sociodemographics contribute to this difference, including country of residence, with Germany having the highest absenteeism and Italy having the highest degree of impairment on each of the other indexes.
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